FDA medical reviewers ask members of the Peripheral and Central Nervous System Drugs Advisory Committee to confirm the benefits and risks of Eisai/Biogen’s Leqembi in treating early Alzheimer’s disease.
Five Hogan Lovells attorneys explain how an FDA proposal to require Patient Medication Information would represent a significant change in drug labeling.
FDA medical reviewers ask members of the Peripheral and Central Nervous System Drugs Advisory Committee to confirm the benefits and risks of Eisai/Biogen’s Leqembi in treating early Alzheimer’s disease.
Five Hogan Lovells attorneys explain how an FDA proposal to require Patient Medication Information would represent a significant change in drug labeling.
FDA warns Houston, TX-based physician Mobeen Mazhar about violations in conducting three clinical trials.
CBER updates information for regulated entities on the return to normal operations with the end of the Covid-19 public health emergency.
